-
Mediolanum Farmaceutici SpA, a privately owned company that leads the Mediolanum Farmaceutici Group of companies, and Genovax srl, a private company which belongs to the portfolio of Eporgen Venture and was originated from the University of Genoa, announced the acquisition by Mediolanum of the global rights to GX301, Genovax’s therapeutic vaccine to treat various types of cancer. The first clinical study with GX301 was successfully completed earlier this year in prostate and renal cancer patients. Further clinical studies are scheduled to be initiated in the next few months, and all future development and commercialization activities will be the responsibility of Mediolanum with the support of Genovax.
Leggi tutto
-
TOP (Transgenic Operative Products) S.r.l. announced that it has signed an agreement to promote and market 3 of its products in North America (U.S. and Canada) with Charles River Laboratories International, Inc., a world leader provider of models for biological research and pharmaceutical industry.
Under this agreement, Charles River has become the exclusive supplier for North America of three TOP S.r.l. products, licensed products will maintain their original brand (repTOP™). This agreement will allow access to TOP S.r.l. to the North American biotechnology market through the Charles River extensive sales network.
Leggi tutto
-
Nicox S.A. (NYSE Euronext Paris: COX) announced its United States (US) launch of AdenoPlus(TM), the first and only FDA-cleared, CLIA-waived, rapid point-of-care diagnostic test that aids in the differential diagnosis of acute conjunctivitis. AdenoPlus(TM) is Nicox's first product launch since it announced its strategy of becoming an international, late-stage development and commercial ophthalmic business, reflected by a new visual identity also unveiled today.
AdenoPlus(TM) accurately detects adenovirus, which accounts for up to 90% of all viral conjunctivitis, and approximately one out of four cases of acute conjunctivitis seen by eyecare practitioners.
Leggi tutto
-
ViroStatics, a private Italian/American biopharmaceutical company developing novel therapeutics for viral and other chronic diseases, announced that a review of the first human clinical trial to test a new class of anti-HIV medications known as AntiViral-HyperActivation Limiting Therapeutics (AV-HALTs) has been published in the peer-reviewed journal PLoS ONE.
The Phase 2a study demonstrated that markers of immune system hyperactivation driving HIV disease progression can be rapidly and effectively reduced by AV-HALTs, resulting in a proportional restoration of immune system damage.
Leggi tutto